IVUS + NIRS: The PROSPECT II Study

The PROSPECT II study was presented as Late-Breaking Clinical Trials during TCT Connect 2020

Click  The PROSPECT II Study for presentation

Latest News:

EUKON FT1000 ranking 2022 on Financial Times

FT 1000: the sixth annual list of Europe’s fastest-growing companies…

Read More >

EUKON Leader della Crescita 2022

Leader della Crescita is  rank of first 450 companies, done…

Read More >

Next Generation PCI - Symposia at GISE 42, Milan 7th Oct 2021

EUKON and SMT present Next Generation PCI Symposia at GISE…

Read More >